A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

NCT02233543 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: QVA149
DRUG: QVA149 Placebo

Sponsor

Novartis Pharmaceuticals